文献速递慢性肾脏病

中低收入国家在CKD药物试验中的代表性:系统综述

Representation of Low- and Middle-Income Countries in CKD Drug Trials: A Systematic Review.
PubMed 文献 · Am J Kidney Dis · 2024-08-06

该研究系统综述了2003-2023年MEDLINE索引的CKD药物随机对照试验,评估世界银行收入组和地理区域的参与情况。在1366项试验中,中低收入国家参与占34.7%,低收入国家无参与,中低收入国家参与者占25.4%;尽管参与趋势上升,但中低收入国家代表性仍不足。

要点

  • 中低收入国家参与CKD药物RCT的比例仅为34.7%,低收入国家完全缺席。
  • 中低收入国家参与者占25.4%,且多数国家相对于CKD患病率代表性不足。
  • 中低收入国家参与呈上升趋势,从2003-2007年的22.9%升至2018-2023年的45.5%。

核心结论

  • 尽管过去20年中低收入国家参与有所增加,但CKD患者在中低收入国家药物RCT中代表性仍显著不足。

研究设计与样本

  • 系统综述,纳入2003-2023年MEDLINE索引的CKD药物RCT,共1366项试验,覆盖84个国家、301158名参与者。

主要发现

  • 国家、区域和全球性RCT分别占85.4%、3.5%和11.1%。
  • 中低收入国家参与34.7%的RCT,低收入国家无参与,中低收入国家参与13.2%。
  • 有信息的RCT参与者中25.4%(64843/255237)来自中低收入国家。
  • 根据代表性指数,6个中低收入国家过度代表,7个充分代表,26个代表不足。
  • 全球CKD RCT中80.2%包含中低收入国家,但中低收入国家参与者仅占32.9%;参与率从2003-2007年的22.9%升至2018-2023年的45.5%。

临床怎么用

  • 临床医生应意识到CKD药物证据主要来自高收入国家,应用于中低收入国家患者时需谨慎考虑代表性不足的影响。

局限性

  • 使用收入组二分法,排除非随机干预研究,仅检索一个数据库。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Almost 80% of individuals with chronic kidney disease (CKD) reside in low- and middle-income countries (LMICs) and are potentially underrepresented in randomized controlled clinical trials (RCTs). We assessed the global distribution of RCTs comparing pharmacological treatments for CKD over the past 2 decades, as well as the magnitude and evolution of participation by LMICs. STUDY DESIGN: Systematic review. SETTING & STUDY POPULATIONS: RCTs evaluating pharmacological interventions in adults with CKD. SELECTION CRITERIA FOR STUDIES: RCTs published between 2003-2023 and indexed in MEDLINE. DATA EXTRACTION: Each trial was reviewed and extracted independently by 2 investigators with disagreements settled by consensus or a third reviewer. ANALYTICAL APPROACH: RCT participation of World Bank-defined income groups and geographic regions were described, and the representation indices (RI) according to RCT participants and estimated CKD prevalences were calculated. RCTs were also categorized as global, regional, or national in scope. RESULTS: Among 7,760 identified studies, we included 1,366 RCTs conducted in 84 countries with 301,158 participants. National, regional, and global RCTs represented 85.4%, 3.5%, and 11.1% of studies, respectively. LMICs were included in 34.7% of RCTs. No RCTs included participants from low-income countries, and lower-middle-income countries participated in 13.2%. Of participants from RCTs with available information, 25.4% (n=64,843 of 255,237) were from LMICs. According to the RI, 6 LMICs were overrepresented (>1.25), 7 were adequately represented (0.75-1.25), and 26 were underrepresented (<0.75). Most global CKD RCTs (80.2%) included LMICs; however, LMIC participants constituted only 32.9% of the global trial population. We observed a positive trend in LMIC inclusion over time, rising from 22.9% (n=71of 310) in 2003-2007 to 45.5% (n=140of 308) in 2018-2023. LIMITATIONS: The use of an income-group dichotomy, exclusion of nonrandomized studies of intervention, and studies identified in 1 database. CONCLUSIONS: Despite an increase in participation over the past 2 decades, individuals with CKD from LMICs remain significantly underrepresented in RCTs. These findings suggest that increased efforts are warranted to increase LMIC representation in pharmacological CKD RCTs. PLAIN-LANGUAGE SUMMARY: Chronic kidney disease (CKD) substantially affects people from low- and middle-income countries (LMICs). However, the participation of these countries in randomized controlled trials (RCTs) remains uncertain. To assess the global distribution and representation of these countries in kidney disease research, we reviewed 1,366 CKD drug RCTs published from 2003-2023, conducted in 84 countries involving more than 300,000 participants. LMICs were included in approximately a third of these studies, with their participants making up approximately one-quarter of the total; lower-middle-income countries were poorly represented, and low-income countries were absent. LMICs constituted a third of participants in multinational RCTs. Most LMICs were underrepresented relative to the prevalence of CKD. We observed an increasing inclusion of LMICs, particularly in the last decade. Nonetheless, individuals with CKD from LMICs remain underrepresented in drug RCTs, suggesting that increased efforts are warranted to include representation of these populations in these studies.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Cojuc-Konigsberg G, Guijosa A, Moscona-Nissan A, et al. Representation of Low- and Middle-Income Countries in CKD Drug Trials: A Systematic Review. Am J Kidney Dis. 2024. PMID: 39117096. doi:10.1053/j.ajkd.2024.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。